Evolution of monoclonal gammopathy of undetermined significance in patients treated with JAK inhibitors for rheumatic diseases: data from the MAJIK-SFR registry
Authors' conclusion
This study provides reassuring and promising data on MGUS evolution in patients treated with JAKis for rheumatic diseases
Study context
- Population
- Patients with monoclonal abnormality prior to JAKi initiation for an active rheumatic disease (RA n = 15, PsA n = 3, axial SpA n = 2), French MAJIK-SFR Registry17 with measurable spike
- Participants
- 20 patients
- Outcome
- Evolution of serum monoclonal protein level (monoclonal gammopathy of undetermined significance (MGUS)) under JAKi
- Follow-up
- 4-28 months
Methodological detailsmulticentre, registry-based
- Multicentre
- Registry-based
Main finding
As reported in the abstract
Serum monoclonal protein level
Decreased
8 of 17 patients
47%
Remained stable
8 patients
47%
Increased
1 patient
6%
Observational data: associations, not effects.
Further findings
Maximal decrease observed · month 14
- Initial IgG kappa of 2.3 g/dl, decreasing to 0.2 g/dl
Original publication
Evolution of monoclonal gammopathy of undetermined significance in patients treated with JAK inhibitors for rheumatic diseases: data from the MAJIK-SFR registry. Rheumatology (Oxford). Published 4 August 2023. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →